• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pixie Dust Technologies Inc.

    7/31/24 4:05:03 PM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PXDT alert in real time by email
    6-K 1 ea0210250-6k_pixiedust.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2024

     

    Commission File Number 001-41749

     

    PIXIE DUST TECHNOLOGIES, INC.

    (Translation of registrant’s name into English)

     

    Pixie Dust Technologies, Inc.

    2-2-1 Yaesu, Chuo-ku

    Tokyo, 104-0028, Japan

    (Address of principal executive officer)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    ☒ Form 20-F        ☐ Form 40-F

     

     

     

     

     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Pixie Dust Technologies, Inc. (the “Company”) held its Annual General Meeting of Shareholders (the “Annual Meeting”) on July 31, 2024 at 3:30 p.m., Japan Standard Time (July 31, 2024 at 2:30 a.m., U.S. Eastern Standard Time) in Tokyo, Japan. The proposals considered at the Annual Meeting are described in detail in the Notice of Convocation (the “Notice”) included as Exhibit 99.1 to the Company’s report on Form 6-K as filed with the U.S. Securities and Exchange Commission on July 5, 2024. Present at the Annual Meeting in person or by proxy were holders of 10,759,784 shares of the Company’s common stock, representing at least one-third (1/3) of the issued and outstanding shares the Company’s common stock as of April 30, 2024, the record date for the Annual Meeting, and constituting a quorum under the Company’s Articles of Incorporation and the Companies Act of Japan. The following proposals were voted upon, and the final results in respect of each such proposal are set forth below:

     

    1. Election of Five (5) Directors

     

    Each of the following five nominees were elected to serve on the Company’s Board of Directors (Yoichi Ochiai, Taiichiro Murakami and Takayuki Hoshi as Directors, Yusuke Murata and Masayo Takahashi as Outside Directors), effective July 31, 2024, in connection with the following voting results:

     

    Nominee   For   Against   Abstain   Broker Non-Votes
    Yoichi Ochiai   10,757,962   1,822   182,400   3,926,883
    Taiichiro Murakami   10,757,962   1,822   182,400   3,926,883
    Takayuki Hoshi   10,757,962   1,822   182,400   3,926,883
    Yusuke Murata   10,759,422   362   182,400   3,926,883
    Masayo Takahashi   10,759,422   362   182,400   3,926,883

     

    2. Issuance and allocation of the 9th series of stock acquisition rights without compensation

     

    Stockholders voted to approve issuance and allocation of the 9th series of stock acquisition rights without compensation, as described in the Notice, in connection with the following voting results:

     

    For   Against   Abstain   Broker Non-Votes
    10,759,311   473   182,400   3,926,883

     

    1

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      PIXIE DUST TECHNOLOGIES, INC.
         
    Date: July 31, 2024 By: /s/ Yoichi Ochiai
      Name: Yoichi Ochiai
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $PXDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PXDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Pixie Dust Technologies Announces CFO Transition

      NEW YORK and TOKYO, March 13, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, announced the appointment of Nobuhiro Takagi and Nobufusa Tarumi as co-Chief Financial Officer ("co-CFO"), effective March 13, 2024. Messrs. Takagi and Tarumi succeed Mr. Mamoru Miwa, whose resignation was not the result of any disagreement or conflict with the Company, its operations, policies, or practices. The role of the Company's Chief Accounting Officer ("CAO"), previously held by Nobuhiro Takagi, will be assumed by the co-CFOs.

      3/13/24 4:05:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Financials

    Live finance-specific insights

    See more
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024

      NEW YORK and TOKYO, Feb. 11, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Monday, February 12, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/11/24 12:48:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024

      NEW YORK and TOKYO, Feb. 6, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Tuesday, February 13, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/6/24 9:00:00 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    SEC Filings

    See more
    • SEC Form 6-K filed by Pixie Dust Technologies Inc.

      6-K - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/25/24 8:00:20 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Pixie Dust Technologies Inc.

      25 - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/4/24 4:30:02 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.

      6-K/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      10/24/24 1:55:49 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:11:11 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:08:59 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:06:35 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • /C O R R E C T I O N -- Pixie Dust Technologies/

      This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release. (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission. NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Te

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

      NEW YORK and TOKYO, Oct. 23, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows: 1.                  Reasons for Applying for Delisting The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets an

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care